Table 4. Association of gene-base subtypes of GEPNEC* and first-line regimens.

GEPNEC types	Regimens	% (n/N)
		ORR	DCR
GEPNEC, gastroenteropancreatic neuroendocrine carcinoma; ORR, overall response rate; DCR, disease control rate; SCLC, small-cell lung cancer; SCNEC, small-cell NEC; LCNEC, large-cell NEC; EP, etoposide and platinum; *, among stage IV, 76 patients had recorded first-line therapy. SCLC-like type, GEPNEC patients with TP53 and RB1 co-mutation (n=27); Non-SCLC-like, GEPNEC patients except for SCLC-like type (n=49); Other regimens mainly included irinotecan-based or oxaplatin-based therapy, which were commonly applied in gastrointestinal adenocarcinoma.
Genomic-based subtype
SCLC-like	EP	50.0 (11/22)	81.8 (18/22)
	Other	0 (0/5)	40.0 (2/5)
Non-SCLC-like	EP	18.9 (7/37)	73.0 (27/37)
	Other	33.3 (4/12)	75.0 (9/12)
Pathological-based subtype
SCNEC	EP	30.8 (12/39)	82.0 (32/39)
	Other	33.3 (2/6)	50.0 (3/6)
LCNEC	EP	25.0 (3/12)	58.3 (7/12)
	Other	21.1 (4/19)	63.2 (12/19)